Speculative biotech play. Being that I have roots in trading biotechs, I felt really good about the Phase 3 clinical trial results that were scheduled to be released in late Nov. Obviously, the ultimate results were beyond my control, so there was some luck involved. Trials met primary and secondary endpoints. A great trade, 225% gain. Held these calls a little over 2 months and very much worth it. Also, sold towards the high of the day, which was great.